We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
- Authors
Findlow, Jamie; Borrow, Ray; Snape, Matthew D; Dawson, Tom; Holland, Ann; John, Tessa M; Evans, Anita; Telford, Karen L; Ypma, Ellen; Toneatto, Daniela; Oster, Philipp; Miller, Elizabeth; Pollard, Andrew J
- Abstract
In the absence of an efficacious broadly protective vaccine, serogroup B Neisseria meningitidis (MenB) is the leading cause of bacterial meningitis and septicemia in many industrialized countries. An investigational recombinant vaccine that contains 3 central proteins; Neisserial adhesin A (NadA), factor H binding protein (fHBP) and Neisserial heparin binding antigen (NHBA) has been developed. These antigens have been formulated with and without outer membrane vesicles (rMenB+OMV and rMenB, respectively) from the New Zealand epidemic strain (B:4:P1.7-2,4). In this trial, we assessed the immunogenicity of these formulations in infants, who are at greatest risk of contracting MenB disease.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Vol 51, Issue 10, p1127
- ISSN
1537-6591
- Publication type
Journal Article
- DOI
10.1086/656741